Thyrotropinsecreting pituitary adenoma

##plugins.themes.academic_pro.article.sidebar##

Published Mar 4, 2015
Download
pdf
Vol. 92 No. 11 (2014): Issue Nov 2014

##plugins.themes.academic_pro.article.main##

Ben Dhaou Besma
Daoud Fatma
Aydi Zohra
Baili Lilia
Ketari Sonia
Ben Amor Golstom
Boussema Fatma
Rokbani Lilia

##plugins.themes.academic_pro.article.details##

References

  1. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropinsecreting pituitary tumors. Endocr Rev 1996;17:610-38
  2. Buchfelder M. Thyrotroph pituitary adenomas. Endocrinologist 2002;12:117-25
  3. Bertherat J, Brue T, Enjalbert A, et al. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in-vivo and in-vitro hormonal secretion. J Clin Endocrinol Metab 1992;75:540-6.
  4. Caron P, Arlot S, Bauters C, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:2849-53
  5. Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85:1487-91.